Synthesis and structures of urea-coordinated dinickel(II) complexes with binucleating ligand 1,3-bis(N-(2-(dimethylamino)ethyl)-N-methylamino)propan-2-ol (HL1) and its analogs

Add time:08/22/2019    Source:sciencedirect.com

New urea-coordinated dinickel(II) complexes with binucleating ligands—HL1, which contains dimethylaminoethyl arms, and its analogs HL2, which features bis(methoxyethyl) arms, and HL3, which contains one dimethylaminoethyl arm and one bis(methoxyethyl) arm—all of which contain a 2-hydroxytrimethylene bridge between the two chelating sites, were synthesized. The structures of [Ni2L1(μ-CH3COO)(CH3COO)(urea)(EtOH)]BPh4·EtOH (2), [Ni2L1(μ-Cl)2(urea)(CH3CN)]BPh4·H2O (3), [Ni2L2(H2O)2(urea)Cl](BPh4)2·H2O (5), and [Ni2L3(μ-CH3COO)2(urea)]BPh4 (7) were revealed by X-ray crystallography, as well as those of their parent dinickel(II) complexes, [Ni2L1(μ-CH3COO)(CH3COO)(H2O)2]BPh4 (1), [Ni2L2(μ-CH3COO)2]BPh4·CH3CN (4), and [Ni2L3(μ-CH3COO)(CH3COO)(EtOH)]BPh4 (6). One urea molecule was coordinated to one dinuclear nickel(II) ion, forming intramolecular hydrogen bonds with a μ-acetato bridge (2, 7), a μ-chloro bridge (3), and coordinated chloro and aqua ligands (5). The formation of 7 from the reaction of 6 with urea was associated with a change in coordination mode from a non-bridging acetato ligand to a μ-acetato ligand. Magnetic measurements revealed a weak antiferromagnetic interaction between the two nickel(II) ions in 1 (J = −16.7 cm−1) and 2 (J = −15.0 cm−1).

We also recommend Trading Suppliers and Manufacturers of 2-(2-methylamino-ethyl)-2H-phthalazin-1-one (cas 113582-15-3). Pls Click Website Link as below: cas 113582-15-3 suppliers

Prev:Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}acetamide: Synthesis, binding affinity and intrinsic activity for MT1 and MT2 melatonin receptors
Next:Research paperDiscovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer)